| Document Date: 2012-07-10 13:07:46
Open Document File Size: 95,83 KBShare Result on Facebook
City Toronto / / Company Spectral Diagnostics / Eli Lilly / GlaxoSmithKline / Mechanism Phase Targeting / Eisai / Lilly / Astra / London-Based GlobalData / Asahi Kasei Pharma / Nature America Inc. / Atox Bio / AstraZeneca / / Country Germany / France / Japan / Russia / United States / Canada / / Currency USD / / Event FDA Phase / Product Recall / Product Issues / / Facility Massachusetts General Hospital / Texas A&M Health Science Center / College Station / / IndustryTerm bacterial products / drugs or devices / / MedicalCondition disease / severe sepsis / inflammatory modulators / tumor necrosis / septic shock / infection / future infections / inflammation / infectious disease / inflammatory responses / sepsis / / MedicalTreatment hemoperfusion / drug therapies / / Organization Texas A&M Health Science Center / Massachusetts General Hospital in Boston / / Person Steven LaRosa / Williams Antiseptic / Shaw Warren / Santosh Mishra / Paul Walker / Sarah C P Williams / / Position infectious disease specialist / chief executive / infectious disease physician / analyst / prime mediator / chief executive of Spectral / / Product pioglitazone / Xigris / Toraymyxin Spectral Diagnostics Antibiotic / Actos / Japan / CD28 / US / / Technology alpha / antibodies / /
SocialTag |
After Xigris, researchers look to new targets to combat sepsis